Pills join the GLP‑1 club
GLP‑1 weight‑loss pills are no longer fringe — Yale Medicine says oral GLP‑1s have become a serious treatment category and experts are explaining how pills compare with injections for efficacy, convenience, and side effects. (Yale Medicine’s explainer on GLP‑1 weight‑loss pills was published April 10, 2026.) (yalemedicine.org)
For years, these drugs were mostly shots because the medicine is fragile, and stomach acid can chew it up before it reaches the bloodstream. Yale Medicine says new pill designs now protect the drug long enough to be absorbed, which is why oral weight-loss versions have moved from experiment to real treatment option. (yalemedicine.org) The drug class is called glucagon-like peptide-1, which is the body’s own “I’m getting full” signal after a meal. These medicines copy that signal, slow how fast food leaves the stomach, cut appetite, and help control blood sugar. (yalemedicine.org) The first pill and the first shot do not solve the same chemistry problem in the same way. Oral Wegovy uses semaglutide, the same peptide drug used in injections, while Foundayo uses orforglipron, a small-molecule drug that is less likely to be broken down during digestion. (yalemedicine.org) That difference changes how the pills fit into a day. Yale Medicine says Foundayo can be taken once daily with or without food, while oral Wegovy has stricter timing rules because more of the drug is lost in the digestive tract before absorption. (yalemedicine.org) This is no longer a one-company market. The Food and Drug Administration approved Wegovy tablets in 2025, and on April 1, 2026, it approved Eli Lilly’s Foundayo, a once-daily orforglipron pill for adults with obesity or adults with overweight plus at least one weight-related condition. (fda.gov 1) (fda.gov 2) The two products also come with different dose ladders. Yale Medicine says oral Wegovy comes in four strengths from 1.5 milligrams to 25 milligrams, while Foundayo comes in six strengths from 0.8 milligrams to 17.2 milligrams. (yalemedicine.org) The weight-loss numbers are now close enough to injections that doctors have to compare tradeoffs instead of dismissing pills. In the phase 3 OASIS 1 trial published in The Lancet in 2023, adults taking oral semaglutide 50 milligrams lost an average of 15.1% of body weight at 68 weeks, versus 2.4% with placebo. (thelancet.com) Foundayo’s approved label is built around a lower average effect, but still far beyond older diet pills. The Food and Drug Administration said Eli Lilly’s phase 3 program supported approval after placebo-adjusted weight loss of roughly 9 to 11 percentage points at 72 weeks, with higher doses producing larger losses. (ajmc.com) The side-effect story looks familiar because the biology is familiar. Yale Medicine says the pills cause the same main stomach problems seen with shots, including nausea, vomiting, diarrhea, constipation, and acid reflux, especially when the dose is being increased. (yalemedicine.org) The warnings are familiar too. The Food and Drug Administration label for Wegovy says semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents and should not be used in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. (fda.gov) What changes for patients is not the basic promise of the drug but the friction of taking it. A weekly shot asks for one needle every seven days, while a daily pill asks for 365 decisions a year, and Yale Medicine says the best choice often comes down to how much convenience, routine, side effects, and expected weight loss matter for one person. (yalemedicine.org)
